Genentech Inc Drug Patent Portfolio
Genentech Inc owns 5 orange book drugs protected by 51 US patents with Evrysdi having the least patent protection, holding only 7 patents. And Rozlytrek with maximum patent protection, holding 14 patents. Given below is the list of Genentech Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11925648 | Solid dosage form having excellent stability | 21 Apr, 2041 | Active |
| US12122789 | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | 15 Apr, 2041 | Active |
| US12064438 | Pharmaceutical preparation excellent in light stability and dissolution property | 09 Oct, 2039 | Active |
| US11534444 | Treatment of SMA | 04 Oct, 2038 | Active |
| US12350273 | 01 Oct, 2038 | Active | |
| US11261198 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | 25 Sep, 2038 | Active |
| US10398693 | Pharmaceutical compositions and dosage forms | 18 Jul, 2038 | Active |
| US11253515 | Pharmaceutical compositions and dosage forms | 18 Jul, 2038 | Active |
| US12410189 | 14 Jun, 2038 | Active | |
| US11028100 | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | 26 Apr, 2038 | Active |
| US10759814 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | 09 Aug, 2037 | Active |
| US11306106 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | 09 Aug, 2037 | Active |
| US10738037 | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | 18 May, 2037 | Active |
| US11091469 | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | 18 May, 2037 | Active |
| US10590102 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone | 30 Dec, 2036 | Active |
| US11254649 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | 30 Dec, 2036 | Active |
| US10478400 | Immediate-release tablets containing combimetinib and methods of making and using the same | 29 Dec, 2036 | Active |
| US11938136 | Compositions for treating spinal muscular atrophy | 08 Nov, 2036 | Active |
| US10851091 | Benzoxazepin oxazolidinone compounds and methods of use | 01 Jul, 2036 | Active |
| US11760753 | Benzoxazepin oxazolidinone compounds and methods of use | 01 Jul, 2036 | Active |
| US9650393 | Benzoxazepin oxazolidinone compounds and methods of use | 01 Jul, 2036 | Active |
| US10590102 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone | 30 Jun, 2036 | Active |
| US11254649 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | 30 Jun, 2036 | Active |
| US10478400 | Immediate-release tablets containing combimetinib and methods of making and using the same | 29 Jun, 2036 | Active |
| US10392406 | Substituted polycyclic pyridone derivatives and prodrugs thereof | 27 Apr, 2036 | Active |
| US10633397 | Substituted polycyclic pyridone derivatives and prodrugs thereof | 27 Apr, 2036 | Active |
| US11827646 | Compounds for treating spinal muscular atrophy | 25 Jan, 2036 | Active |
| US9969754 | Compounds for treating spinal muscular atrophy | 11 May, 2035 | Active |
| US10561651 | Methods for treating neuroblastoma | 19 Feb, 2035 | Active |
| US10231965 | Molecules for administration to ROS1 mutant cancer cells | 17 Feb, 2035 | Active |
| US11087354 | Combination therapies | 22 Dec, 2034 | Active |
| US11087354 | Combination therapies | 22 Jun, 2034 | Active |
| US9085565 | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | 22 May, 2033 | Active |
| US9649306 | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | 22 May, 2033 | Active |
| US9586955 | Compounds for treating spinal muscular atrophy | 08 Feb, 2033 | Active |
| US8299057 | Substituted indazole derivatives active as kinase inhibitors | 10 Mar, 2032 | Active |
| US8987441 | Substituted polycyclic carbamoyl pyridone derivative prodrug | 21 Sep, 2031 | Active |
| US8927710 | Substituted polycyclic carbamoylpyridone derivative | 05 May, 2031 | Active |
| US8242104 | Benzoxazepin P13K inhibitor compounds and methods of use | 27 Sep, 2030 | Active |
| US8343955 | Benzoxazepin PI3K inhibitor compounds and methods of use | 27 Sep, 2030 | Active |
| US9815835 | Substituted polycyclic carbamolypyridone derivative | 14 Jun, 2030 | Active |
| US7803839 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 10 May, 2030 | Active |
| US7803839 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 10 Nov, 2029 | Active |
| US8673893 | Substituted indazole derivatives active as kinase inhibitors | 08 Jul, 2028 | Active |
| US9029356 | Substituted indazole derivatives active as kinase inhibitors | 08 Jul, 2028 | Active |
| US9085558 | Substituted indazole derivatives active as kinase inhibitors | 08 Jul, 2028 | Active |
| US9255087 | Substituted indazole derivatives active as kinase inhibitors | 08 Jul, 2028 | Active |
| US9616059 | Substituted indazole derivatives active as kinase inhibitors | 08 Jul, 2028 | Active |
| US8362002 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 05 Apr, 2027 | Active |
| US11597699 | MEK inhibitors and methods of their use | 05 Oct, 2026 | Active |
| US8362002 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 05 Oct, 2026 | Active |
Latest Legal Activities on Genentech Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Genentech Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jul, 2024 | US8362002 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Apr, 2024 | US8299057 |
| Recordation of Patent eGrant | 26 Mar, 2024 | US11938136 |
|
Recordation of Patent Grant Mailed
Critical
| 26 Mar, 2024 | US11938136 |
| Sequence Moved to Public Database | 26 Mar, 2024 | US11938136 |
| Patent eGrant Notification | 26 Mar, 2024 | US11938136 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 26 Mar, 2024 | US11938136 |
| Mail Patent eGrant Notification | 26 Mar, 2024 | US11938136 |
|
Email Notification
Critical
| 26 Mar, 2024 | US11938136 |
| Mail Patent eGrant Notification | 12 Mar, 2024 | US11925648 |
| Recordation of Patent eGrant | 12 Mar, 2024 | US11925648 |
| Patent eGrant Notification | 12 Mar, 2024 | US11925648 |
|
Email Notification
Critical
| 12 Mar, 2024 | US11925648 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Mar, 2024 | US11925648 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Mar, 2024 | US11925648 |
Genentech Inc Drug Patents' Oppositions Filed in EPO
Genentech Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 05, 2012, by Eip Limited. This opposition was filed on patent number EP06825554A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP13753131A | Mar, 2020 | Sandoz AG | Opposition rejected |
| EP06825554A | Jan, 2012 | EIP Limited | Opposition rejected |
Genentech Inc's Family Patents
Genentech Inc drugs have patent protection in a total of 45 countries. It's US patent count contributes only to 16.6% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Genentech Inc Drug List
Given below is the complete list of Genentech Inc's drugs and the patents protecting them.
1. Cotellic
Cotellic is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10590102
(Pediatric)
| Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
30 Dec, 2036
(11 years from now)
| Active |
| US11254649
(Pediatric)
| Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
30 Dec, 2036
(11 years from now)
| Active |
| US10478400
(Pediatric)
| Immediate-release tablets containing combimetinib and methods of making and using the same |
29 Dec, 2036
(11 years from now)
| Active |
| US10590102 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
30 Jun, 2036
(10 years from now)
| Active |
| US11254649 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
30 Jun, 2036
(10 years from now)
| Active |
| US10478400 | Immediate-release tablets containing combimetinib and methods of making and using the same |
29 Jun, 2036
(10 years from now)
| Active |
| US11087354
(Pediatric)
| Combination therapies |
22 Dec, 2034
(9 years from now)
| Active |
| US11087354 | Combination therapies |
22 Jun, 2034
(8 years from now)
| Active |
| US7803839
(Pediatric)
| Azetidines as MEK inhibitors for the treatment of proliferative diseases |
10 May, 2030
(4 years from now)
| Active |
| US7803839 | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
10 Nov, 2029
(3 years from now)
| Active |
| US8362002
(Pediatric)
| Azetidines as MEK inhibitors for the treatment of proliferative diseases |
05 Apr, 2027
(1 year, 3 months from now)
| Active |
| US11597699 | MEK inhibitors and methods of their use |
05 Oct, 2026
(9 months from now)
| Active |
| US8362002 | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
05 Oct, 2026
(9 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cotellic's drug page
2. Evrysdi
Evrysdi is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12122789 | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
15 Apr, 2041
(15 years from now)
| Active |
| US11534444 | Treatment of SMA |
04 Oct, 2038
(12 years from now)
| Active |
| US12350273 |
01 Oct, 2038
(12 years from now)
| Active | |
| US11938136 | Compositions for treating spinal muscular atrophy |
08 Nov, 2036
(10 years from now)
| Active |
| US11827646 | Compounds for treating spinal muscular atrophy |
25 Jan, 2036
(10 years from now)
| Active |
| US9969754 | Compounds for treating spinal muscular atrophy |
11 May, 2035
(9 years from now)
| Active |
| US9586955 | Compounds for treating spinal muscular atrophy |
08 Feb, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evrysdi's drug page
3. Itovebi
Itovebi is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12410189 |
14 Jun, 2038
(12 years from now)
| Active | |
| US11028100 | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
26 Apr, 2038
(12 years from now)
| Active |
| US10851091 | Benzoxazepin oxazolidinone compounds and methods of use |
01 Jul, 2036
(10 years from now)
| Active |
| US11760753 | Benzoxazepin oxazolidinone compounds and methods of use |
01 Jul, 2036
(10 years from now)
| Active |
| US9650393 | Benzoxazepin oxazolidinone compounds and methods of use |
01 Jul, 2036
(10 years from now)
| Active |
| US8242104 | Benzoxazepin P13K inhibitor compounds and methods of use |
27 Sep, 2030
(4 years from now)
| Active |
| US8343955 | Benzoxazepin PI3K inhibitor compounds and methods of use |
27 Sep, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Itovebi's drug page
4. Rozlytrek
Rozlytrek is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10398693 | Pharmaceutical compositions and dosage forms |
18 Jul, 2038
(12 years from now)
| Active |
| US11253515 | Pharmaceutical compositions and dosage forms |
18 Jul, 2038
(12 years from now)
| Active |
| US10738037 | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
18 May, 2037
(11 years from now)
| Active |
| US11091469 | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
18 May, 2037
(11 years from now)
| Active |
| US10561651 | Methods for treating neuroblastoma |
19 Feb, 2035
(9 years from now)
| Active |
| US10231965 | Molecules for administration to ROS1 mutant cancer cells |
17 Feb, 2035
(9 years from now)
| Active |
| US9085565 | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
22 May, 2033
(7 years from now)
| Active |
| US9649306 | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
22 May, 2033
(7 years from now)
| Active |
| US8299057 | Substituted indazole derivatives active as kinase inhibitors |
10 Mar, 2032
(6 years from now)
| Active |
| US8673893 | Substituted indazole derivatives active as kinase inhibitors |
08 Jul, 2028
(2 years from now)
| Active |
| US9029356 | Substituted indazole derivatives active as kinase inhibitors |
08 Jul, 2028
(2 years from now)
| Active |
| US9085558 | Substituted indazole derivatives active as kinase inhibitors |
08 Jul, 2028
(2 years from now)
| Active |
| US9255087 | Substituted indazole derivatives active as kinase inhibitors |
08 Jul, 2028
(2 years from now)
| Active |
| US9616059 | Substituted indazole derivatives active as kinase inhibitors |
08 Jul, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rozlytrek's drug page
5. Xofluza
Xofluza is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11925648 | Solid dosage form having excellent stability |
21 Apr, 2041
(15 years from now)
| Active |
| US12064438 | Pharmaceutical preparation excellent in light stability and dissolution property |
09 Oct, 2039
(13 years from now)
| Active |
| US11261198 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
25 Sep, 2038
(12 years from now)
| Active |
| US10759814 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
09 Aug, 2037
(11 years from now)
| Active |
| US11306106 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
09 Aug, 2037
(11 years from now)
| Active |
| US10392406 | Substituted polycyclic pyridone derivatives and prodrugs thereof |
27 Apr, 2036
(10 years from now)
| Active |
| US10633397 | Substituted polycyclic pyridone derivatives and prodrugs thereof |
27 Apr, 2036
(10 years from now)
| Active |
| US8987441 | Substituted polycyclic carbamoyl pyridone derivative prodrug |
21 Sep, 2031
(5 years from now)
| Active |
| US8927710 | Substituted polycyclic carbamoylpyridone derivative |
05 May, 2031
(5 years from now)
| Active |
| US9815835 | Substituted polycyclic carbamolypyridone derivative |
14 Jun, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xofluza's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List